Inclusion of carbohydrate antigen 242 in addition to carbohydrate antigen 19.9 in serological workup of carcinoma gall bladder: a case series analysis
DOI:
https://doi.org/10.18203/2320-6012.ijrms20233700Keywords:
CA 242, Gall bladder cancer, Tumor antigens, CA19.9, ELISAAbstract
Background: Common antigenic pool is seen because of shared embryonic origins of gall bladder cancer (GBC) and pancreas. Hence, we analyzed the role of serum carbohydrate antigen 242 (CA242) which has been studied in pancreatic cancer, in GBC. The objectives were to identify whether serum CA242 provides added advantage in diagnosis of GBC when compared to controls and to determine its cut-off value.
Methods: Serum CA 19-9 level was determined by chemiluminescent micro particle assay and CA242 by enzyme linked immunosorbent assay (ELISA) of age matched cases and controls.
Results: Total enrolled patients were 83 including 10 (11.7%) healthy volunteers, 22 (25.9%) chronic cholecystitis cases, and 53 (62.4%) patients with histological evidence of carcinoma. Mean age of presentation of GBC was 51.64 SD10.88 years with F: M ratio of 5.6:1. Pain (90.6%, 48/53) accompanied with jaundice was significantly associated with GBC well reflected by significantly raised serum total bilirubin (p=0.011), direct bilirubin (p=0.008) along with alkaline phosphatase levels (p=0.001). Significantly higher median value of CA 19-9 and CA242 was observed in GBC when compared to CC and healthy volunteers (p<0.001) with a significant correlation between tumor size (>2.5 cm) and serum levels of CA242. The best cut-off limit for CA242 was 45.25 IU/ml. The specificity for carcinoma diagnosis increased to 100% when CA242 was included along with CA 19.9 in serological estimation.
Conclusions: We recommend that CA antigen 19-9 may be complimented with CA242 for serological identification of malignancy in the gall bladder.
References
Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer. 2006;1:1591-602.
Perpetuo MD, Valdivieso M, Heilbrun LK, Nelson RS, Connor T, Bodey GP. Natural history study of gallbladder cancer: a review of 36 years experience at M. D. Anderson Hospital and Tumor Institute. Cancer. 1978;14242:1-330.
Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 2014;7:99-109.
Kapoor VK, McMichael AJ: Gallbladder cancer: an 'Indian' disease. Natl Med J India. 2003;16:209-13.
Phadke P, Mhatre S, Budukh A, Dikshit RP. Trends in gallbladder cancer incidence in the high- and low-risk regions of India. Indian J Med Paediatr Oncol. 2019;41:90.
Dhir V, Mohandas KM. Epidemiology of digestive tract cancers in India IV. Gall bladder and pancreas. Indian J Gastroenterol. 1999;18:24-8.
Ausania F, Tsirlis T, White SA, French JJ, Jaques BC, Charnley RM, Manas DM. Incidental pT2-T3 gallbladder cancer after a cholecystectomy: outcome of staging at 3 months prior to a radical resection. HPB (Oxford). 2013;15(8):633-7.
Gupta S, Prakash P, Kumar V, Chaturvedi A, Misra S, Akhtar N, et al. Radical surgery for de novo gallbladder carcinoma-Single-center analysis of prognostic factors and survival outcomes from an endemic region. J Surg Oncol. 2022;125(4):631-41.
Zhu AX, Hong TS, Hezel AF, Kooby DA. Current management of gallbladder carcinoma. Oncologist. 2010;15(2):168-81.
Yildirim E, Celen O, Gulben K, Berberoglu U. The surgical management of incidental gallbladder carcinoma. Eur J Surg Oncol. 2005;31:45-52.
Agarwal P, Raghuvanshi S, Yadav S, Bhalla S. Role of Endoscopic Retrograde Cholangiopancreatography Guided Brush Cytology in Evaluation of Malignant Biliary Tract Strictures: Experience of Tertiary Care Teaching Centre in Northern India. J Clin Diagnost Res. 2018;12:14-8.
Giannini E, Borro P, Botta F, Chiarbonello B, Fasoli A, Malfatti F, et al. Cholestasis is the main determinant of abnormal CA 19-9 levels in patients with liver cirrhosis. Int J Biol Markers. 2000;15:226-30.
Hong JY, Jang SH, Kim SY, Chung KS, Song JH, Park MS, et al. Elevated serum CA 19-9 levels in patients with pulmonary nontuberculous mycobacterial disease. Braz J Infect Dis. 2016;20:26-32.
Bhattarai A, Jha B, Timilsina S. Serum CA 19-9 Levels in Benign and Malignant Diseases Associated with the Gastrointestinal Tract. Ann Clin Chem Lab Med. 2015;1:35-41.
Yadav K, Agarwal P, Kumar M, Gupta S, Mishra M, Maurya MK, et al. Immunohistochemical appraisal of epithelial mesenchymal transition type III in gall bladder cancer. Indian J Pathol Microbiol. 2023;66(1):44-53.
Hamdani NH, Qadri SK, Aggarwalla R, Bhartia VK, Chaudhuri S, Debakshi S, et al. Clinicopathological study of gall bladder carcinoma with special reference to gallstones: our 8-year experience from eastern India. Asian Pac J Cancer Prev. 2012;13(11):5613-7.
Rana S, Dutta U, Kochhar R. Evaluation of CA 242 as a tumor marker in gallbladder cancer. J Gastrointest Cancer. 2012;43:267-71.
Vitetta L, Sali A, Little P, Mrazek L. Gallstones and gall bladder carcinoma. Aust N Z J Surg. 2000;70:667-73.
Agrawal S, Lawrence A, Saxena R. Does CA 19-9 Have Prognostic Relevance in Gallbladder Carcinoma (GBC)?. J Gastrointest Cancer. 2018;49:144-9.
Chang CW, Cheng CH, Wang TE, Chen CJ, Liu CY, Hung CY, et al. Impact of Therapeutic Interventions on Survival of Elderly Patients with Gallbladder Carcinoma: A 10-year Single Center Experience. Int J Gerontol. 2015;9:228-32.
Kankonkar SR, Joshi SV, Deshpande RR. Significance of tumour markers in cancer of gall bladder. OJI. 2013;3(19):33.
Yano V, Basak S, Das KA. Clinicopathological Study of Gallbladder Carcinoma with Special Emphasis on Correlation of Serum Ca 19-9 Level to Staging. SAS J Surg. 2017;3:154-64.
Liu F, Wang JK, Ma WJ, Yang Q, Hu HJ, Li FY. Clinical value of preoperative CA19-9 levels in evaluating resectability of gallbladder carcinoma. ANZ J Surg. 2019;89:76-80.
Lee JW, Kim YT, Lee SH, Son JH, Kang JW, Ryu JK, et al. Tumor Marker Kinetics as Prognosticators in Patients with Unresectable Gallbladder Adenocarcinoma Undergoing Palliative Chemotherapy. Gut Liver. 2018;15:102-10.
Wen Z, Si A, Yang J. Elevation of CA19-9 and CEA is associated with a poor prognosis in patients with resectable gallbladder carcinoma. HPB. 2017;19:951-6.
Shukla VK, Gurubachan, Sharma D, Dixit VK, Usha. Diagnostic value of serum CA242, CA 19-9, CA 15-3 and CA 125 in patients with carcinoma of the gallbladder. Trop Gastroenterol. 2006;27:160-5.
Wang YF, Feng FL, Zhao XH. Combined detection tumor markers for diagnosis and prognosis of gallbladder cancer. World J Gastroenterol. 2014;14:4085-92.
Agarwal A, Tiwari V, Kumari S, Husain N. Prognostic value of CA19-9 and CA242 in gallbladder cancer - an exploratory study. IJCMR. 2019;6:242.
Zhuang PY, Zhu MJ, Wang JD. Xanthogranulomatous cholecystitis: a clinicopathological study of its association with gallbladder carcinoma. J Dig Dis. 2013;14:45-50.
Ballard DH, Cho J, Zhao H. Comparisons of multi-marker association methods to detect association between a candidate region and disease. Genet Epidemiol. 2010;34(3):201-12.
